Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2022, Cilt: 52 Sayı: 2, 143 - 147, 30.08.2022

Öz

Kaynakça

  • Arnet, I., & Hersberger, K. E. (2010). Misleading score-lines on tab- lets: Facilitated intake or fractional dosing? Swiss Medical Weekly, 140(7-8), 105-110. https://doi.org/smw-12953
  • Cook, T. J., Edwards, S., Gyemah, C., Shah, M., Shah, I., & Fox, T. (2004). Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets. Journal of the Ameri- can Pharmacists Association: JAPhA, 44(5), 583-586. https://doi. org/10.1331/1544-3191.44.5.583.cook
  • Elliott, I., Mayxay, M., Yeuichaixong, S., Lee, S. J., & Newton, P. N. (2014). The practice and clinical implications of tablet splitting in international health. Tropical Medicine & International Health: TM & IH, 19(7), 754-760. https://doi.org/10.1111/tmi.12309
  • FDA. (2013). Best Practices for Tablet Splitting. https://www.fda.gov/ drugs/ensuring-safe-use-medicine/best-practices-tablet-splitting
  • Haywood, A., & Glass, B. D. (2011). Pharmaceutical excipients – where do we begin? Australian Prescriber, 34(4), 112-114. https:// doi.org/10.18773/austprescr.2011.060
  • Johnson, J. A. (2012). Warfarin pharmacogenetics: A rising tide for its clinical value. Circulation, 125(16), 1964-1966. https://doi. org/10.1161/CIRCULATIONAHA.112.100628
  • Palcsó, B., & Zelkó, R. (2018). Different types, applications and lim- its of enabling excipients of pharmaceutical dosage forms. Drug Discovery Today. Technologies, 27, 21-39. https://doi.org/10.1016/j. ddtec.2018.04.002
  • Rowley F. (s. f.). Minimize Bisect Risk: Part I. Oct 06, 2006. https:// www.pharmamanufacturing.com/articles/2006/188/
  • Shah, R. B., Collier, J. S., Sayeed, V. A., Bryant, A., Habib, M. J., & Khan, M. A. (2010). Tablet splitting of a narrow therapeutic index drug: A case with levothyroxine sodium. AAPS PharmSciTech, 11(3), 1359- 1367. https://doi.org/10.1208/s12249-010-9515-8
  • Spiller, H. A., Klein-Schwartz, W., Colvin, J. M., Villalobos, D., John- son, P. B., & Anderson, D. L. (2005). Toxic clonidine ingestion in children. The Journal of Pediatrics, 146(2), 263-266. https://doi. org/10.1016/j.jpeds.2004.09.027
  • Thompson, C. A. (2012). New term will distinguish tablets known to split in half. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharma- cists, 69(19), 1619-1621. https://doi.org/10.2146/news120071
  • United States Pharmacopeial Convention Inc. (2018). USP 41-NF 36. En United States Pharmacopeia and National For- mulary. https://www.deutscher-apotheker-verlag.de/shop/ produkt/9783769270228/usp-41-nf-36-the-united-states-phar- macopeia-and-national-formulary-2018
  • Veronin, M. A., & Youan, B.-B. C. (2004). Medicine. Magic bullet gone astray: Medications and the Internet. Science (New York, N.Y.), 305(5683), 481. https://doi.org/10.1126/science.1097355
  • Verrue, C., Mehuys, E., Boussery, K., Remon, J.-P., & Petrovic, M. (2011). Tablet-splitting: A common yet not so innocent practice. Journal of Advanced Nursing, 67(1), 26-32. https://doi.org/10.1111/ j.1365-2648.2010.05477.x

The practice of dividing tablets: An uncertain act

Yıl 2022, Cilt: 52 Sayı: 2, 143 - 147, 30.08.2022

Öz

Background and Aims: Tablets can be split by patients for a number of reasons, using various instruments. Tablets can be scored or unscored; if scored, they may be split into pieces, and in spite of guidelines to do so patients are still at risk of re- sultant drug dose fluctuations, or being exposed to toxic or subtherapeutic doses. The aim of this study was to investigate differences in weight between halves of tablets, split by different populations and with different devices.
Methods: 3-factor full factorial design (3 runs) was used with participants: patients, caregivers, nurses, medical doctors, and pharmacists; instruments: scissors, tablet cutters, knives, hand; drugs: losartan, clonidine, metoprolol, and warfarin. The risk of unequal tablet splitting was estimated and analyzed for each factor and their interaction with linearized general- ized models.
Results: Differences in weight were found to be above 15% and 25% of the theoretical weight as in general, the highest weight variations after splitting were found in clonidine with patients using scissors. The overall risk of non-equal tablet splitting was 22.5% for deviations > 15% and for > 25%.
Conclusion: In this study, no tablet was split into halves of equal weight; based on these findings, splitting tablets is a ques- tionable practice.

Kaynakça

  • Arnet, I., & Hersberger, K. E. (2010). Misleading score-lines on tab- lets: Facilitated intake or fractional dosing? Swiss Medical Weekly, 140(7-8), 105-110. https://doi.org/smw-12953
  • Cook, T. J., Edwards, S., Gyemah, C., Shah, M., Shah, I., & Fox, T. (2004). Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets. Journal of the Ameri- can Pharmacists Association: JAPhA, 44(5), 583-586. https://doi. org/10.1331/1544-3191.44.5.583.cook
  • Elliott, I., Mayxay, M., Yeuichaixong, S., Lee, S. J., & Newton, P. N. (2014). The practice and clinical implications of tablet splitting in international health. Tropical Medicine & International Health: TM & IH, 19(7), 754-760. https://doi.org/10.1111/tmi.12309
  • FDA. (2013). Best Practices for Tablet Splitting. https://www.fda.gov/ drugs/ensuring-safe-use-medicine/best-practices-tablet-splitting
  • Haywood, A., & Glass, B. D. (2011). Pharmaceutical excipients – where do we begin? Australian Prescriber, 34(4), 112-114. https:// doi.org/10.18773/austprescr.2011.060
  • Johnson, J. A. (2012). Warfarin pharmacogenetics: A rising tide for its clinical value. Circulation, 125(16), 1964-1966. https://doi. org/10.1161/CIRCULATIONAHA.112.100628
  • Palcsó, B., & Zelkó, R. (2018). Different types, applications and lim- its of enabling excipients of pharmaceutical dosage forms. Drug Discovery Today. Technologies, 27, 21-39. https://doi.org/10.1016/j. ddtec.2018.04.002
  • Rowley F. (s. f.). Minimize Bisect Risk: Part I. Oct 06, 2006. https:// www.pharmamanufacturing.com/articles/2006/188/
  • Shah, R. B., Collier, J. S., Sayeed, V. A., Bryant, A., Habib, M. J., & Khan, M. A. (2010). Tablet splitting of a narrow therapeutic index drug: A case with levothyroxine sodium. AAPS PharmSciTech, 11(3), 1359- 1367. https://doi.org/10.1208/s12249-010-9515-8
  • Spiller, H. A., Klein-Schwartz, W., Colvin, J. M., Villalobos, D., John- son, P. B., & Anderson, D. L. (2005). Toxic clonidine ingestion in children. The Journal of Pediatrics, 146(2), 263-266. https://doi. org/10.1016/j.jpeds.2004.09.027
  • Thompson, C. A. (2012). New term will distinguish tablets known to split in half. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharma- cists, 69(19), 1619-1621. https://doi.org/10.2146/news120071
  • United States Pharmacopeial Convention Inc. (2018). USP 41-NF 36. En United States Pharmacopeia and National For- mulary. https://www.deutscher-apotheker-verlag.de/shop/ produkt/9783769270228/usp-41-nf-36-the-united-states-phar- macopeia-and-national-formulary-2018
  • Veronin, M. A., & Youan, B.-B. C. (2004). Medicine. Magic bullet gone astray: Medications and the Internet. Science (New York, N.Y.), 305(5683), 481. https://doi.org/10.1126/science.1097355
  • Verrue, C., Mehuys, E., Boussery, K., Remon, J.-P., & Petrovic, M. (2011). Tablet-splitting: A common yet not so innocent practice. Journal of Advanced Nursing, 67(1), 26-32. https://doi.org/10.1111/ j.1365-2648.2010.05477.x
Toplam 14 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Eczacılık ve İlaç Bilimleri
Bölüm Original Article
Yazarlar

David Galvis Pareja Bu kişi benim 0000-0001-8458-7547

Clara Ines Manrique Bu kişi benim 0000-0003-2605-1634

Diego Rojas Gualdron Bu kişi benim 0000-0002-2293-0431

Heidy Contreras Bu kişi benim 0000-0003-2049-4864

Yayımlanma Tarihi 30 Ağustos 2022
Gönderilme Tarihi 9 Haziran 2020
Yayımlandığı Sayı Yıl 2022 Cilt: 52 Sayı: 2

Kaynak Göster

APA Pareja, D. G., Manrique, C. I., Gualdron, D. R., Contreras, H. (2022). The practice of dividing tablets: An uncertain act. İstanbul Journal of Pharmacy, 52(2), 143-147.
AMA Pareja DG, Manrique CI, Gualdron DR, Contreras H. The practice of dividing tablets: An uncertain act. iujp. Ağustos 2022;52(2):143-147.
Chicago Pareja, David Galvis, Clara Ines Manrique, Diego Rojas Gualdron, ve Heidy Contreras. “The Practice of Dividing Tablets: An Uncertain Act”. İstanbul Journal of Pharmacy 52, sy. 2 (Ağustos 2022): 143-47.
EndNote Pareja DG, Manrique CI, Gualdron DR, Contreras H (01 Ağustos 2022) The practice of dividing tablets: An uncertain act. İstanbul Journal of Pharmacy 52 2 143–147.
IEEE D. G. Pareja, C. I. Manrique, D. R. Gualdron, ve H. Contreras, “The practice of dividing tablets: An uncertain act”, iujp, c. 52, sy. 2, ss. 143–147, 2022.
ISNAD Pareja, David Galvis vd. “The Practice of Dividing Tablets: An Uncertain Act”. İstanbul Journal of Pharmacy 52/2 (Ağustos 2022), 143-147.
JAMA Pareja DG, Manrique CI, Gualdron DR, Contreras H. The practice of dividing tablets: An uncertain act. iujp. 2022;52:143–147.
MLA Pareja, David Galvis vd. “The Practice of Dividing Tablets: An Uncertain Act”. İstanbul Journal of Pharmacy, c. 52, sy. 2, 2022, ss. 143-7.
Vancouver Pareja DG, Manrique CI, Gualdron DR, Contreras H. The practice of dividing tablets: An uncertain act. iujp. 2022;52(2):143-7.